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background
 
Results from observational studies suggest that micronutrient status is a determinant
of the progression of human immunodeficiency virus (HIV) disease.
 
methods
 
We enrolled 1078 pregnant women infected with HIV in a double-blind, placebo-con-
trolled trial in Dar es Salaam, Tanzania, to examine the effects of daily supplements of
vitamin A (preformed vitamin A and beta carotene), multivitamins (vitamins B, C, and E),
or both on progression of HIV disease, using survival models. The median follow-up
with respect to survival was 71 months (interquartile range, 46 to 80). 
 
results
 
Of 271 women who received multivitamins, 67 had progression to World Health Orga-
nization (WHO) stage 4 disease or died — the primary outcome — as compared with
83 of 267 women who received placebo (24.7 percent vs. 31.1 percent; relative risk,
0.71; 95 percent confidence interval, 0.51 to 0.98; P=0.04). This regimen was also as-
sociated with reductions in the relative risk of death related to the acquired immunode-
ficiency syndrome (0.73; 95 percent confidence interval, 0.51 to 1.04; P=0.09), pro-
gression to WHO stage 4 (0.50; 95 percent confidence interval, 0.28 to 0.90; P=0.02),
or progression to stage 3 or higher (0.72; 95 percent confidence interval, 0.58 to 0.90;
P=0.003). Multivitamins also resulted in significantly higher CD4+ and CD8+ cell
counts and significantly lower viral loads. The effects of receiving vitamin A alone were
smaller and for the most part not significantly different from those produced by place-
bo. Adding vitamin A to the multivitamin regimen reduced the benefit with regard to
some of the end points examined.
 
conclusions
 
Multivitamin supplements delay the progression of HIV disease and provide an effec-
tive, low-cost means of delaying the initiation of antiretroviral therapy in HIV-infected
women.
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t the end of 2003, approximately
 
40 million people worldwide were infect-
ed with human immunodeficiency virus
(HIV), many of whom had symptoms of the ac-
quired immunodeficiency syndrome (AIDS).
 
1
 
 Few-
er than 8 percent of the 6 million patients with ad-
vanced disease who were eligible for antiretroviral
treatment were receiving it. The “Treat 3 Million by
2005” initiative of the World Health Organization
(WHO) is designed to increase access to treatment.
 
2
 
According to this plan and country-specific stan-
dards of care, patients with advanced disease will re-
ceive antiretroviral treatment, while those in earlier
stages will be monitored and given supportive care.
Micronutrient supplements have been proposed
as low-cost immunomodulating interventions that
may slow the progression of HIV disease.
 
3,4
 
 If effi-
cacious, supplements could delay the onset of ad-
vanced disease and the need for antiretroviral ther-
apy, saving antiretroviral drugs for when they may
be most needed and reducing drug-related adverse
events and costs. Therefore, we examined the ef-
fect of micronutrient supplements — vitamin A
alone, multivitamins including vitamin B complex
and vitamins C and E, and multivitamins plus vita-
min A — on the risks of clinical disease progres-
sion, HIV-related complications, CD4+ cell counts,
and viral load in HIV-positive women in Tanzania.
We enrolled 1078 HIV-infected pregnant women in
Dar es Salaam, Tanzania, over a two-year period
starting in April 1995. Women were followed from
enrollment until the end of the study in August
2003. The design of the trial has been described in
detail (the randomization scheme and outcomes
are shown in the Supplementary Appendix, avail-
able with the full text of this article at www.
nejm.org).
 
5
 
 In brief, eligible women were random-
ly assigned in blocks of 20 to receive a daily oral
dose of one of four regimens for the duration of
follow-up: vitamin A alone (30 mg of beta carotene
plus 5000 IU of preformed vitamin A), multivita-
mins excluding vitamin A (20 mg of vitamin B
 
1
 
,
20 mg of vitamin B
 
2
 
, 25 mg of vitamin B
 
6
 
, 100 mg
of niacin, 50 µg of vitamin B
 
12
 
, 500 mg of vitamin C,
30 mg of vitamin E, and 0.8 mg of folic acid), mul-
tivitamins plus vitamin A in the same doses listed
above, or placebo. All women received standard
doses of antenatal folic acid and iron. At delivery,
women in the two groups that received vitamin A
were given an additional oral dose of vitamin A
(200,000 IU), whereas the women in the other two
groups were given a placebo. All children received
a dose of vitamin A every six months, according to
the standard of care in Tanzania. Active tablets and
placebo were identical in size and color. All clinical
and follow-up staff were unaware of the women’s
treatment assignments. At the time of the study,
antiretroviral therapy was not available to the ma-
jority of women in Tanzania, including those who
participated in the study.
Women were followed through monthly visits to
a study clinic, where physicians performed a physi-
cal examination. A study nurse inquired about the
health of the woman in the preceding period, in-
cluding signs of HIV-related complications. Diar-
rhea was defined as three or more watery stools in
the prior 24 hours. Dysentery was defined as an ep-
isode of diarrhea with mucus or blood. Weight,
height, and the circumference of the middle of the
upper arm were determined. The stage of HIV was
assessed at each visit in accordance with the WHO
criteria on the basis of the woman’s history and
physical examination.
 
6
 
 For women who did not at-
tend the clinic or who traveled out of Dar es Salaam,
a home visit was made and neighbors or relatives
were asked about vital status. No data on compli-
cations were collected at these visits. To approxi-
mate the cause of death, we used verbal-autopsy
techniques by conducting standardized interviews
with relatives, reviewing medical records, or both.
The cause of death was ascertained in a blinded
fashion. Data on women whose cause of death
could not be ascertained or for whom death was
deemed unrelated to AIDS were censored at the
time of death. A total of 343 women died during
follow-up. Of these deaths, 243 were deemed to be
due or related to AIDS: 82 were due to AIDS, 61 to
pulmonary tuberculosis, 3 to extrapulmonary tuber-
culosis, 10 to anemia, 14 to meningitis, 5 to stroke,
23 to pneumonia, 21 to diarrhea, and 24 to fever.
Because enrollment occurred over a period of two
years, the maximal duration of follow-up for each
woman varied accordingly. The median duration of
follow-up with respect to survival was 71 months
(interquartile range, 46 to 80).
A blood specimen was requested at baseline and
every six months thereafter for the measurement of
T-cell subgroups (CD4+, CD8+, and CD3+) with
the use of the FACScount and FACSCAN systems
(Becton Dickinson). A mean (±SD) of 7.8±4.9 mea-
surements were available for each woman (median,
a
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8). We selected a random sample of 300 women to
examine the effect of supplements on viral load.
For these women, a minimum of three blood sam-
ples (baseline, last sample at the time of selection,
and the sample at approximately the midpoint be-
tween the two) were analyzed. Data from a small,
previously analyzed subgroup were included; thus,
some women contributed more than three speci-
mens to the analysis. For women who died, we
used the last sample that had been obtained at least
six months before death as the final sample to
avoid using specimens obtained during terminal
illness. The data set for the final analysis com-
prised 1051 specimens from 297 women who had
adequate baseline specimens and at least one or
more viral-load measurements. Viral load was quan-
tified with the use of the Roche Amplicor version
1.5 assay. A mean of 2.8±1.5 measurements were
available for each woman (median, 3). The number
of women and the average number of measure-
ments of viral load per woman were similar in the
four groups (P=0.89 and P=0.88, respectively).
The primary aims were to compare the effects of
multivitamins, vitamin A alone, and both with those
of placebo. A factorial design was used to maxi-
mize statistical power. The sample size was calcu-
lated to examine the efficacy of the supplements on
mother-to-child (vertical) transmission of HIV and
on disease progression, assuming a 30 percent in-
cidence of each outcome. Given the primary aims
specified in the original protocol, we examined as
the primary strategy the effects of each treatment
on disease progression, as compared with those of
placebo. Also, given our subsequent observation of
a significantly higher risk of vertical transmission
of HIV type 1 among women receiving vitamin
A,
 
7,8
 
 the remaining question of interest with re-
spect to public health was the efficacy of multivita-
mins as compared with that of placebo.
We compared baseline characteristics in the
four groups using an F test (SAS GLM procedure)
for continuous variables and the chi-square test for
categorical variables. We used proportional-haz-
ards regression models to investigate the effects of
the supplements on the time to the predefined pri-
mary clinical outcome of progression to WHO stage
4 or death from AIDS-related causes, whichever oc-
curred first.
 
9
 
 We also compared the times to the
following end points: death from AIDS-related
causes, progression to WHO stage 4, progression
to WHO stage 3 or higher, or an increase of at least
two stages from baseline. For these outcomes, fol-
low-up ended on the date on which the stage was
last assessed. One woman in WHO stage 4 at ran-
domization was excluded from these analyses. We
also examined whether the effects of the regimens
on the primary end point were modified by maternal
baseline characteristics dichotomized using con-
ventional cutoff points for CD4+ cells (fewer than
350 vs. at least 350 per cubic millimeter) and plasma
vitamin A (less than 0.7 µmol per liter vs. at least
0.7 µmol per liter), or the median value of plasma
vitamin E (less than 9.7 µmol per liter vs. at least
9.7 µmol per liter) and the circumference of the
middle of the upper arm (25 cm) as another marker
of maternal nutritional status.
We compared effects of the supplements on
T-cell counts (CD4+, CD8+, and CD3+), viral load,
and individual signs of disease, including condi-
tions ascertained by study physicians at clinic visits,
such as thrush, gingival erythema, angular cheilitis,
oral ulcers, and acute upper respiratory tract infec-
tion. Clinical signs reported during the month be-
fore visits included ulcers in the mouth and throat,
painful tongue or mouth, difficult or painful swal-
lowing, nausea and vomiting, diarrhea, dysentery,
fatigue, and rash. Effects of supplements on com-
plications, T-cell counts, and viral load were ana-
lyzed with the use of generalized estimating equa-
tions and SAS Proc Genmod software.
 
10
 
To assess the effectiveness of treatment over
time, we analyzed data for the whole period, the
first two years, and the first four years. A data and
safety monitoring board reviewed the progress of
the study and the results of interim analyses. Given
earlier findings from the trial indicating beneficial
effects of the multivitamin regimen in reducing ad-
verse outcomes of pregnancy,
 
11
 
 all women who be-
came pregnant after May 1998 were given open-
label multivitamins throughout pregnancy; these
women reverted to their prepregnancy blinded reg-
imen after delivery. In September 2000, the data
and safety monitoring board recommended that vi-
tamin A be dropped from the two vitamin A–con-
taining regimens because increased transmission
of HIV to children was found to be associated with
maternal vitamin A supplementation.
 
7
 
 Subsequent-
ly, women randomly assigned to receive vitamin A
alone or with multivitamins received placebo alone
or with multivitamins, respectively. All analyses
were conducted according to the intention to treat,
and P values are two-sided. We performed second-
ary analyses censoring all data on September 30,
2000, the date the data and safety monitoring board
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recommended dropping the vitamin A treatment.
The results were essentially the same; hence, only
primary analyses are presented.
All women gave oral or written informed consent
to participate in the study according to a strict pro-
tocol that was approved by the institutional review
boards. The institutional review boards of Muhim-
bili University College of Health Sciences, the Tan-
zanian National AIDS Control Program, and Har-
vard School of Public Health approved the study
protocol. None of the sponsors of the study had any
role in the study design, data collection, data analy-
sis, data interpretation, or writing of the report.
The baseline characteristics of the four groups
were similar, including age, level of education, he-
moglobin levels, CD4+ and CD8+ cell counts, and
plasma levels of vitamins A and E (Table 1). Com-
pliance, evaluated as the number of tablets absent
from the returned bottles at monthly visits divided
by the total number of tablets the woman should
have taken, was high: 79 percent over the total pe-
riod of follow-up, 83 percent at two years, and 80
percent at four years. Compliance was similar in all
groups.
A total of 299 of the 1078 women progressed to
WHO stage 4 or died of AIDS-related causes: 67 of
271 women who received multivitamins (24.7 per-
cent), 70 of 268 who received multivitamins plus
vitamin A (26.1 percent), 79 of 272 who received vi-
tamin A alone (29.0 percent), and 83 of 267 wom-
en who received placebo (31.1 percent) (Table 2).
As compared with women in the placebo group,
those in the multivitamin group were significantly
results
 
* Plus–minus values are means ±SD. There were no significant differences among the groups.
† Data on viral load were available for 300 randomly selected women and an additional 115 women (from a previously analyzed subgroup) for 
 
whom baseline values were measured. A base-10 scale was used.
 
Table 1. Baseline Characteristics of the Women.*
Characteristic Placebo (N=267)
Multivitamins 
(N=271)
Multivitamins + Vitamin A 
(N=268)
Vitamin A Alone
(N=272)
 
Age (yr) 24.7±4.7 24.6±4.8 24.8±4.6 24.6±5.0
Level of education (%)
None or adult education
1–4 yr
5–8 yr
>8 yr
8.3
5.6
79.0
7.1
10.3
6.3
72.7
10.7
7.1
3.7
77.3
11.9
7.4
4.4
77.9
10.3
Prior pregnancies (%)
0
1–3
>3
23.6
60.4
16.0
30.2
57.2
12.6
23.0
63.4
13.6
29.0
54.7
16.3
WHO disease stage (%)
1
2
3
82.4
16.1
1.5
81.8
18.2
0
80.4
18.1
1.5
77.8
19.6
2.6
CD4+ cell count (%)
0 to 199/mm
 
3
 
200 to 349/mm
 
3
 
≥350/mm
 
3
 
13.9
21.7
64.4
11.8
21.2
67.0
13.5
26.6
59.9
12.0
28.2
59.8
Circumference of middle of upper arm (cm) 25.4±2.9 25.7±2.9 25.5±2.8 25.6±3.0
CD4+ cell count/mm
 
3 
 
429±224 433±199 411±205 417±201
CD8+ cell count/mm
 
3 
 
770±363 739±329 1223±446 748±313 
CD3+ cell count/mm
 
3 
 
1260±504 1226±445 1223±446 1225±434
Erythrocyte sedimentation rate (mm/hr) 62.6±37.9 57.8±36.3 58.0±34.7 56.7±35.4
Viral load (log)† 4.58±0.89 4.56±0.78 4.62±0.83 4.66±0.77
Hemoglobin (g/liter) 96±17 93±16 93±16 94±17
Plasma vitamin A (µmol/liter) 0.88±0.42 0.85±0.34 0.87±0.31 0.85±0.34
Plasma vitamin E (µmol/liter) 10.0±3.1 10.0±3.0 10.2±3.0 9.9±3.2 
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on February 19, 2014. For personal use only. No other uses without permission. 
 Copyright © 2004 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
351;1
 
www.nejm.org july 
 
1, 2004
 
multivitamin supplementation and hiv disease progression
 
27
 
*
Th
e 
re
la
tiv
e 
ri
sk
s,
 9
5 
pe
rc
en
t c
on
fid
en
ce
 in
te
rv
al
s 
(C
Is
),
 a
nd
 c
or
re
sp
on
di
ng
 P
 v
al
ue
s 
w
er
e 
ob
ta
in
ed
 fr
om
 a
 s
in
gl
e 
C
ox
 r
eg
re
ss
io
n 
m
od
el
 fo
r 
ea
ch
 o
ut
co
m
e 
co
m
pa
ri
ng
 th
e 
ef
fe
ct
 o
f e
ac
h 
tr
ea
tm
en
t w
ith
 th
at
 o
f t
he
 p
la
ce
bo
 g
ro
up
.
†
Th
e 
m
ea
n 
du
ra
tio
n 
of
 fo
llo
w
-u
p 
w
ith
 re
sp
ec
t t
o 
su
rv
iv
al
 w
as
 6
1.
4 
m
on
th
s 
(m
ed
ia
n,
 7
1;
 in
te
rq
ua
rt
ile
 ra
ng
e,
 4
6 
to
 8
0)
. T
he
 m
ed
ia
n 
du
ra
tio
n 
of
 fo
llo
w
-u
p 
w
ith
 re
sp
ec
t t
o 
th
e 
st
ag
e 
of
 H
IV
 d
is
-
 
ea
se
 w
as
 6
0 
m
on
th
s 
(i
nt
er
qu
ar
til
e 
ra
ng
e,
 1
4 
to
 7
9)
.
 
Ta
bl
e 
2.
 R
el
at
iv
e 
R
is
ks
 o
f D
is
ea
se
 P
ro
gr
es
si
on
 a
nd
 D
ea
th
 fr
om
 A
ID
S-
R
el
at
ed
 C
au
se
s 
am
on
g 
H
IV
-I
nf
ec
te
d 
W
om
en
 R
ec
ei
vi
ng
 O
ne
 o
f T
hr
ee
 V
ita
m
in
 R
eg
im
en
s,
 a
s 
C
om
pa
re
d 
w
ith
 
W
om
en
 in
 th
e 
Pl
ac
eb
o 
G
ro
up
.*
O
ut
co
m
e
N
o.
 o
f 
Ev
en
ts
 in
 
Pl
ac
eb
o 
G
ro
up
M
ul
tiv
ita
m
in
s
M
ul
tiv
ita
m
in
s 
+ 
V
ita
m
in
 A
 
V
ita
m
in
 A
 A
lo
ne
 
N
o.
 o
f 
Ev
en
ts
 
R
el
at
iv
e 
R
is
k 
(9
5%
 C
I)
 
P 
V
al
ue
N
o.
 o
f 
Ev
en
ts
 
R
el
at
iv
e 
R
is
k 
(9
5%
 C
I)
 
P 
V
al
ue
 
N
o.
 o
f 
Ev
en
ts
 
R
el
at
iv
e 
R
is
k 
(9
5%
 C
I)
 
P 
V
al
ue
 
W
ho
le
 p
er
io
d
 
†
Pr
og
re
ss
io
n 
to
 s
ta
ge
 4
 o
r 
de
at
h 
fr
om
 
A
ID
S-
re
la
te
d 
ca
us
es
83
67
0.
71
 (
0.
51
–0
.9
8)
0.
04
70
0.
80
 (
0.
58
–1
.1
0)
0.
17
79
0.
88
 (
0.
64
–1
.1
9)
0.
40
D
ea
th
 fr
om
 A
ID
S-
re
la
te
d 
ca
us
es
66
52
0.
73
 (
0.
51
–0
.0
4)
0.
09
60
0.
91
 (
0.
64
–1
.2
8)
0.
58
65
0.
93
 (
0.
66
–1
.3
2)
0.
70
Pr
og
re
ss
io
n 
to
 s
ta
ge
 4
31
18
0.
50
 (
0.
28
–0
.9
0)
0.
02
22
0.
67
 (
0.
39
–1
.1
5)
0.
15
23
0.
68
 (
0.
40
–1
.1
7)
0.
16
Pr
og
re
ss
io
n 
to
 ≥
st
ag
e 
3
16
6
16
3
0.
72
 (
0.
58
–0
.9
0)
0.
00
3
16
3
0.
79
 (
0.
64
–0
.9
8)
0.
03
16
5
0.
81
 (
0.
65
–1
.0
0)
0.
05
≥2
-s
ta
ge
 in
cr
ea
se
14
5
13
1
0.
66
 (
0.
52
–0
.8
4)
<0
.0
01
13
3
0.
74
 (
0.
59
–0
.9
4)
0.
01
13
4
0.
74
 (
0.
58
–0
.9
3)
0.
01
 
Fi
rs
t t
w
o 
ye
ar
s
 
Pr
og
re
ss
io
n 
to
 s
ta
ge
 4
 o
r 
de
at
h 
fr
om
 
A
ID
S-
re
la
te
d 
ca
us
es
24
11
0.
41
 (
0.
20
–0
.8
5)
0.
02
19
0.
75
 (
0.
41
–1
.3
6)
0.
34
20
0.
76
 (
0.
42
–1
.3
7)
0.
36
D
ea
th
 fr
om
 A
ID
S-
re
la
te
d 
ca
us
es
16
9
0.
54
 (
0.
24
–1
.2
2)
0.
14
13
0.
80
 (
0.
39
–1
.6
7)
0.
55
12
0.
73
 (
0.
34
–1
.5
4)
0.
40
Pr
og
re
ss
io
n 
to
 s
ta
ge
 4
12
2
0.
15
 (
0.
03
–0
.6
8)
0.
01
8
0.
63
 (
0.
26
–1
.5
4)
0.
31
8
0.
61
 (
0.
25
–1
.4
9)
0.
28
Pr
og
re
ss
io
n 
to
 ≥
st
ag
e 
3
10
2
90
0.
71
 (
0.
54
–0
.9
4)
0.
02
91
0.
76
 (
0.
57
–1
.0
1)
0.
06
90
0.
76
 (
0.
57
–1
.0
1)
0.
06
≥2
-s
ta
ge
 in
cr
ea
se
88
68
0.
60
 (
0.
44
–0
.8
3)
0.
00
2
73
0.
69
 (
0.
50
–0
.9
4)
0.
02
69
0.
66
 (
0.
48
–0
.9
1)
0.
01
 
Fi
rs
t f
ou
r 
ye
ar
s
 
Pr
og
re
ss
io
n 
to
 s
ta
ge
 4
 o
r 
de
at
h 
fr
om
 
A
ID
S-
re
la
te
d 
ca
us
es
43
34
0.
72
 (
0.
46
–1
.1
3)
0.
16
39
0.
87
 (
0.
57
–1
.3
5)
0.
54
45
0.
97
 (
0.
64
–1
.4
7)
0.
88
D
ea
th
 fr
om
 A
ID
S-
re
la
te
d 
ca
us
es
33
31
0.
91
 (
0.
56
–1
.4
8)
0.
70
31
0.
94
 (
0.
58
–1
.5
4)
0.
81
33
0.
96
 (
0.
59
–1
.5
6)
0.
88
Pr
og
re
ss
io
n 
to
 s
ta
ge
 4
16
3
0.
17
 (
0.
05
–0
.5
9)
0.
00
5
12
0.
72
 (
0.
34
–1
.5
1)
0.
50
15
0.
87
 (
0.
43
–1
.7
5)
0.
69
Pr
og
re
ss
io
n 
to
 ≥
st
ag
e 
3
14
4
12
7
0.
68
 (
0.
54
–0
.8
6)
<0
.0
01
13
9
0.
80
 (
0.
63
–1
.0
0)
0.
05
14
5
0.
85
 (
0.
67
–1
.0
7)
0.
16
≥2
-s
ta
ge
 in
cr
ea
se
12
3
97
0.
59
 (
0.
45
–0
.7
6)
<0
.0
01
11
5
0.
77
 (
0.
60
–0
.9
9)
0.
04
11
6
0.
77
 (
0.
60
–0
.9
9)
0.
04
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on February 19, 2014. For personal use only. No other uses without permission. 
 Copyright © 2004 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
351;1
 
www.nejm.org july 
 
1
 
, 
 
2004
 
The
 
 new england journal 
 
of
 
 medicine
 
28
 
less likely to progress to WHO stage 4 or die of
AIDS-related causes (relative risk, 0.71; 95 percent
confidence interval, 0.51 to 0.98; P=0.04) (Fig. 1
and Table 2). The effects of receiving vitamin A
alone were smaller and for the most part not signif-
icantly different from those produced by placebo.
As compared with placebo, multivitamins also
had beneficial effects on other outcomes of ad-
vanced disease, including the relative risk of pro-
gression to WHO stage 4 (0.50; 95 percent confi-
dence interval, 0.28 to 0.90; P=0.02) or progression
to stage 3 or higher (0.72; 95 percent confidence
interval, 0.58 to 0.90; P=0.003). The effect of mul-
tivitamins was strongest in the first two years, al-
though the beneficial effects were also observed at
four years (Table 2). We found no evidence that the
effects of multivitamins or vitamin A were signifi-
cantly modified by baseline maternal nutritional
status or CD4+ cell counts.
Multivitamins significantly reduced oral and
gastrointestinal manifestations of HIV disease (Ta-
ble 3). Other benefits included significant reduc-
tions in reported fatigue, rash, and acute upper res-
piratory tract infections. Vitamin A alone had no
significant beneficial effects on any of these symp-
toms and signs.
Overall, the mean CD4+ cell counts were higher
by 48 cells per cubic millimeter among women
who received multivitamins than among those
who received placebo (95 percent confidence inter-
val, 10 to 85; P=0.01) (Table 4). The viral load was
also significantly lower — by 0.18 log (95 percent
confidence interval, ¡0.32 to ¡0.03; P=0.02) —
among women who received multivitamins. Add-
ing vitamin A to the multivitamin regimen reduced
the benefit with regard to the various end points ex-
amined.
In secondary analyses, we compared the use
and nonuse of multivitamins and of vitamin A, us-
ing the factorial structure of the study. Women who
received multivitamins were less likely to progress
to WHO stage 4 or die of AIDS-related causes (rela-
tive risk, 0.80; 95 percent confidence interval, 0.64
to 1.01; P=0.06) than were women who did not re-
ceive multivitamins. In contrast, receipt of vitamin
A, as compared with the absence of vitamin A sup-
plementation, had no significant effect (relative
risk, 0.99; 95 percent confidence interval, 0.79 to
1.24; P=0.90; P for interaction between the two
regimens=0.27). Similar results were noted for pro-
gression to stage 4 (P for interaction=0.11), progres-
sion to stage 3 or higher (P for interaction=0.05),
and a two-stage increase (P for interaction=0.02).
In the first two years, multivitamin supplementa-
tion, as compared with no multivitamin supplemen-
tation, reduced the relative risk of progression to
stage 4 or death from AIDS-related causes (0.66,
P=0.08), whereas vitamin A supplementation, as
compared with no vitamin A supplementation, in-
creased the relative risk (1.07, P=0.77; and P for
interaction=0.07). Multivitamins also significantly
reduced all signs of complications, including oral
ulcers (relative risk, 0.52; P<0.001), angular cheili-
tis (relative risk, 0.44; P<0.001), difficult or painful
swallowing (relative risk, 0.47; P<0.001), dysentery
(relative risk, 0.75; P=0.03), and fatigue (relative
risk, 0.76; P=0.007). Women who received multi-
vitamins also had significantly higher CD4+ cell
counts (by 50 cells per cubic millimeter, P<0.001)
and lower viral loads (by 0.11 log, P=0.05). In con-
trast, vitamin A supplementation, as compared with
no vitamin A supplementation, increased the rela-
tive risks of angular cheilitis (1.51, P=0.04) and
difficult or painful swallowing (1.39, P=0.02) and
resulted in significantly lower CD8+ cell counts
(by 46 cells per cubic millimeter, P=0.04) and
CD3+ cell counts (by 57 cells per cubic millimeter,
P=0.03).
 
Figure 1. Kaplan–Meier Estimates of the Proportion of Women Alive
with Disease at WHO Stage 3 or Lower.
1.0
Pr
op
or
tio
n 
A
liv
e 
w
ith
 W
H
O
 S
ta
ge
 ≤
3
0.8
0.9
0.7
0.6
0
0 12 24 36 48 60 72
Multivitamins
Multivitamins+
vitamin A
Months after Randomization
No. at Risk
Multivitamins
Multivitamins+
vitamin A
Vitamin A alone
Placebo
119 
102 
104 
101
157 
143 
147 
145
195 
181 
190 
173
271 
267 
272 
267
Vitamin A alone
Placebo
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on February 19, 2014. For personal use only. No other uses without permission. 
 Copyright © 2004 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
351;1
 
www.nejm.org july 
 
1, 2004
 
multivitamin supplementation and hiv disease progression
 
29
 
*
Th
e 
re
la
tiv
e 
ri
sk
s,
 9
5 
pe
rc
en
t c
on
fid
en
ce
 in
te
rv
al
s 
(C
Is
),
 a
nd
 c
or
re
sp
on
di
ng
 P
 v
al
ue
s 
w
er
e 
es
tim
at
ed
 fr
om
 g
en
er
al
iz
ed
 e
st
im
at
in
g 
eq
ua
tio
ns
 a
dj
us
te
d 
fo
r 
th
e 
ot
he
r 
re
gi
m
en
s,
 w
ith
 th
e 
pl
a-
ce
bo
 g
ro
up
 s
er
vi
ng
 a
s 
th
e 
re
fe
re
nc
e 
gr
ou
p.
 
†
Pl
us
–m
in
us
 v
al
ue
s 
ar
e 
th
e 
m
ea
n 
(±
SD
) 
nu
m
be
rs
 o
f e
pi
so
de
s 
pe
r 
ye
ar
 p
er
 w
om
an
 (
th
e 
av
er
ag
e 
nu
m
be
r 
of
 e
pi
so
de
s 
pe
r 
vi
si
t¬
12
).
 
Ta
bl
e 
3.
 R
el
at
iv
e 
R
is
ks
 o
f H
IV
-R
el
at
ed
 C
om
pl
ic
at
io
ns
 a
m
on
g 
W
om
en
 A
ss
ig
ne
d 
to
 O
ne
 o
f T
hr
ee
 V
ita
m
in
 R
eg
im
en
s,
 a
s 
C
om
pa
re
d 
w
ith
 W
om
en
 in
 th
e 
Pl
ac
eb
o 
G
ro
up
.*
C
om
pl
ic
at
io
n
Ep
is
od
es
†
R
el
at
iv
e 
R
is
k 
in
 P
la
ce
bo
 G
ro
up
M
ul
tiv
ita
m
in
s 
M
ul
tiv
ita
m
in
s 
+ 
V
ita
m
in
 A
 
V
ita
m
in
 A
 A
lo
ne
 
R
el
at
iv
e 
R
is
k 
(9
5%
 C
I)
 
P 
V
al
ue
 
R
el
at
iv
e 
R
is
k 
(9
5%
 C
I)
 
P 
V
al
ue
 
R
el
at
iv
e 
R
is
k 
(9
5%
 C
I)
 
P 
V
al
ue
Th
ru
sh
0.
14
±0
.4
8
1.
0
0.
47
 (
0.
30
–0
.7
3)
<0
.0
01
0.
58
 (
0.
38
–0
.8
7)
0.
00
8
0.
69
 (
0.
44
–1
.0
7)
0.
10
G
in
gi
va
l e
ry
th
em
a
0.
02
±0
.1
4
1.
0
0.
22
 (
0.
06
–0
.8
3)
0.
02
0.
64
 (
0.
23
–1
.7
9)
0.
40
1.
00
 (
0.
40
–2
.4
6)
0.
99
A
ng
ul
ar
 c
he
ili
tis
0.
11
±0
.4
8
1.
0
0.
45
 (
0.
25
–0
.7
9)
0.
00
6
0.
64
 (
0.
38
–1
.0
9)
0.
10
1.
54
 (
0.
95
–2
.5
1)
0.
08
O
ra
l u
lc
er
0.
10
±0
.3
0
1.
0
0.
44
 (
0.
28
–0
.6
8)
<0
.0
01
0.
54
 (
0.
35
–0
.8
6)
0.
00
9
0.
94
 (
0.
59
–1
.4
8)
0.
78
R
ep
or
te
d 
m
ou
th
 a
nd
 th
ro
at
 u
lc
er
s
0.
28
±0
.9
3
1.
0
0.
47
 (
0.
33
–0
.6
6)
<0
.0
01
0.
64
 (
0.
44
–0
.9
4)
0.
02
1.
01
 (
0.
74
–1
.3
8)
0.
93
Pa
in
fu
l t
on
gu
e 
or
 m
ou
th
0.
31
±0
.9
8
1.
0
0.
46
 (
0.
33
–0
.6
6)
<0
.0
01
0.
61
 (
0.
41
–0
.8
8)
0.
00
9
1.
03
 (
0.
76
–1
.4
0)
0.
85
D
iff
ic
ul
t o
r 
pa
in
fu
l s
w
al
lo
w
in
g
0.
16
±0
.5
5
1.
0
0.
41
 (
0.
26
–0
.6
3)
<0
.0
01
0.
68
 (
0.
46
–1
.0
3)
0.
07
1.
25
 (
0.
88
–1
.7
7)
0.
21
N
au
se
a 
an
d 
vo
m
iti
ng
0.
38
±1
.1
4
1.
0
0.
69
 (
0.
50
–0
.9
7)
0.
03
0.
76
 (
0.
55
–1
.0
4)
0.
08
0.
98
 (
0.
71
–1
.3
5)
0.
91
D
ia
rr
he
a
0.
55
±1
.2
5
1.
0
0.
83
 (
0.
63
–1
.0
9)
0.
18
0.
86
 (
0.
64
–1
.1
4)
0.
29
0.
95
 (
0.
72
–1
.2
5)
0.
71
D
ys
en
te
ry
0.
19
±0
.7
1
1.
0
0.
66
 (
0.
45
–0
.9
5)
0.
03
0.
82
 (
0.
57
–1
.1
9)
0.
29
0.
90
 (
0.
62
–1
.2
8)
0.
54
Fa
tig
ue
0.
59
±1
.4
3
1.
0
0.
64
 (
0.
49
–0
.8
6)
0.
00
3
0.
97
 (
0.
73
–1
.3
0)
0.
84
1.
04
 (
0.
79
–1
.3
5)
0.
79
R
as
h
0.
96
±1
.7
6
1.
0
0.
74
 (
0.
57
–0
.9
6)
0.
02
0.
76
 (
0.
59
–0
.9
8)
0.
03
0.
83
 (
0.
64
–1
.0
6)
0.
13
A
cu
te
 u
pp
er
 r
es
pi
ra
to
ry
 tr
ac
t 
in
fe
ct
io
n
0.
83
±1
.1
3
1.
0
0.
79
 (
0.
66
–0
.9
6)
0.
02
0.
87
 (
0.
73
–1
.0
3)
0.
11
0.
96
 (
0.
80
–1
.1
4)
0.
62
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on February 19, 2014. For personal use only. No other uses without permission. 
 Copyright © 2004 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
351;1
 
www.nejm.org july 
 
1
 
, 
 
2004
 
The
 
 new england journal 
 
of
 
 medicine
 
30
 
Multivitamin supplementation with vitamin B com-
plex, vitamin C, and vitamin E significantly delayed
the progression of disease among HIV-infected
women, as reflected by the relative risk of progres-
sion to WHO stage 4 or death from AIDS-related
causes, as well as other measures of disease pro-
gression. Supplementation with vitamin A alone
had weaker effects that for the most part were not
significantly different from those produced by
placebo.
A relationship between suboptimal micronutri-
ent status and multivitamin use and HIV progres-
sion has been noted in observational studies. In
two longitudinal studies of U.S. men,
 
12-14
 
 higher
intakes of vitamins (including vitamins B
 
1
 
, B
 
2
 
, and
B
 
6
 
; niacin; vitamin C; and vitamin E) were associat-
ed with slower disease progression. Similarly, sup-
plementation with B-complex vitamins was benefi-
cial among black South Africans infected with
HIV.
 
15
 
 U.S. men with lower serum vitamin E levels
 
16
 
or vitamin B
 
12
 
 levels
 
17
 
 were more likely than those
with higher levels to have progression to AIDS.
These findings from observational studies were
questioned, given the potential for residual con-
founding by preclinical disease to explain the ben-
eficial associations.
 
3,4
 
 In a recent study in Thailand,
multivitamin supplementation was associated with
a significant reduction in mortality among patients
with baseline CD4+ cell counts below 100 cells per
cubic millimeter but had no significant effects on
CD4+ cell counts, viral load, or clinical disease pro-
gression.
 
18
 
 The statistical power of the study was
limited by the relatively small sample size (481 pa-
tients and 23 reported deaths) and brief duration
(48 weeks).
In our study, supplementation with multivita-
mins also reduced the incidence of complications
including oral thrush, oral ulcers, and difficulty in
swallowing, which are potential indicators of esoph-
ageal candidiasis and other inflammatory condi-
tions. Nausea, vomiting, and diarrhea were also
less frequent among women who received multivi-
tamins. Oral and gastrointestinal manifestations
are more likely in advanced stages of HIV disease
discussion
 
* Plus–minus values are means ±SD. The baseline measurement was excluded.
† Values are the mean difference between this group and the placebo group. The mean differences, 95 percent confidence intervals (CIs), 
and corresponding P values were estimated from generalized estimating equations, after adjustment for baseline measurements.
 
‡ A base-10 scale was used.
 
Table 4. Effects of Three Vitamin Regimens on T-Cell Counts and Viral Loads, as Compared with the Effects of Placebo.
End Point
Mean Value 
in Placebo Group* Multivitamins Multivitamins + Vitamin A Vitamin A Alone
 
Mean Difference 
(95% CI)† P Value 
Mean Difference 
(95% CI)† P Value 
Mean Difference 
(95% CI)† P Value 
 
Whole period
 
CD4+ cell count/mm
 
3
 
449±255 48 (10 to 85) 0.01 41 (4 to 77) 0.03 ¡15 (¡45 to 14) 0.30
CD8+ cell count/mm
 
3
 
968±479 43 (¡15 to 101) 0.15 12 (¡44 to 69) 0.67 ¡48 (¡100 to 4) 0.07
CD3+ cell count/mm
 
3
 
1497±615 88 (14 to 161) 0.02 47 (¡27 to 120) 0.21 ¡72 (¡141 to ¡3) 0.04
Viral load (log)‡ 4.67±0.86 ¡0.18 (¡0.32 to ¡0.03) 0.02 ¡0.07 (¡0.21 to 0.09) 0.40 ¡0.03 (¡0.17 to 0.11) 0.68
 
First 2 years
 
CD4+ cell count/mm
 
3
 
494±257 48 (18 to 79) 0.002 21 (¡11 to 53) 0.20 ¡16 (¡44 to 13) 0.28
CD8+ cell count/mm
 
3
 
973±425 56 (1 to 110) 0.05 40 (¡18 to 97) 0.17 ¡36 (¡89 to 17) 0.19
CD3+ cell count/mm
 
3
 
1544±587 109 (32 to 185) 0.006 64 (¡15 to 143) 0.11 ¡59 (¡132 to 15) 0.12
Viral load (log)‡ 4.59±0.86 ¡0.18 (¡0.34 to ¡0.03) 0.02 ¡0.11 (¡0.27 to 0.05) 0.17 ¡0.07 (¡0.23 to 0.08) 0.35
 
First 4 years
 
CD4+ cell count/mm
 
3
 
470±254 38 (8 to 68) 0.01 19 (¡12 to 50) 0.22 ¡18 (¡46 to 11) 0.22
CD8+ cell count/mm
 
3
 
959±438 56 (2 to 111) 0.04 31 (¡26 to 87) 0.29 ¡53 (¡105 to ¡1) 0.05
CD3+ cell count/mm
 
3
 
1506±584 98 (25 to 171) 0.009 59 (¡16 to 133) 0.12 ¡71 (¡140 to ¡1) 0.05
Viral load (log)‡ 4.65±0.86 ¡0.18 (¡0.33 to ¡0.04) 0.01 ¡0.09 (¡0.24 to 0.06) 0.24 ¡0.04 (¡0.18 to 0.10) 0.57
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and could interfere with patients’ appetite and total
energy intake in addition to decreasing their quali-
ty of life.
 
19,20
 
 Micronutrients may protect the integ-
rity of oral and gastrointestinal epithelia and en-
hance local and systemic immunity.
 
21
 
We observed significantly higher CD4+, CD8+,
and CD3+ cell counts and lower viral loads among
women who received multivitamins than among
those who received placebo. B vitamins and vita-
mins C and E enhance cellular immunity.
 
22,23
 
 Sig-
nificant positive relationships were observed be-
tween levels of several B vitamins and CD4+ cell
counts among HIV-infected men in the United
States.
 
12,24
 
 Vitamins enhance immune function,
as measured by the levels of antiinflammatory cyto-
kines.
 
25
 
 HIV-positive African women with no clini-
cal manifestations had a vigorous antiinflamma-
tory cytokine response.
 
26
 
 We previously reported
that multivitamins significantly improved CD4+,
CD8+, and CD3+ cell counts up to one year after
randomization.
 
11
 
 Our updated findings indicate
that this beneficial effect was sustained for a medi-
an of five years.
In addition to enhancing immunity, multivita-
mins may also reduce HIV replication, as indicated
by the significant reduction in viral load. HIV repli-
cation in vitro is increased by oxidative stress.
 
27
 
Components of our multivitamin supplement, par-
ticularly vitamins C and E, are potent antioxidants.
In a small, randomized, placebo-controlled study
of 49 HIV-positive patients, those who received
daily supplements of both vitamin E (800 IU) and
vitamin C (1000 mg) for three months had a signif-
icant reduction in lipid peroxidation (a measure of
oxidative stress), with a trend toward a reduced vi-
ral load.
 
28
 
The benefits with respect to immunologic and vi-
rologic outcomes in our study were small relative to
the effects of triple antiretroviral therapy. However,
the effects of multivitamins on the CD4+ cell
counts and viral load were similar to, and in some
cases larger than, those of early trials, which com-
pared therapy with a single antiretroviral agent with
placebo or dual therapy with single-drug treatment,
as well as recent trials comparing three-drug thera-
py with two-drug therapy.
 
29
 
 In a meta-analysis of
studies that evaluated treatment-mediated changes
in CD4+ cell counts and viral load as surrogates for
the progression of HIV disease (progression to
AIDS or death), the relationships between these
markers and the risk of progression were linear.
 
30
 
Applying our observed reduction of 0.18 log in the
viral load to this linear relation results in an in-
crease in the time to progression to AIDS or death
of approximately 30 percent, similar to the size of
the effect that we observed.
Vitamin A alone had no significant effects on
clinical outcomes, T-cell counts, or viral load.
Among HIV-infected U.S. men, the relationship
between vitamin A intake and HIV disease pro-
gression and mortality was 
 
U
 
-shaped, suggesting
that both low and high levels of intake are poten-
tially harmful.
 
13,14
 
 We previously reported that
vitamin A supplements resulted in a significant in-
crease in mother-to-child transmission of HIV.
 
7,8
 
Moreover, in the current study, we found that add-
ing vitamin A to the multivitamin supplement ap-
parently reduced the benefit of the latter regimen,
raising questions about the safety of including vita-
min A in supplements recommended for HIV-infect-
ed adults.
The timing of the initiation of antiretroviral ther-
apy is still controversial. The revised U.S. guidelines
for adults recommend initiation when AIDS-relat-
ed symptoms develop or, for asymptomatic adults,
when CD4+ cell counts drop below 350 per cubic
millimeter or plasma levels of HIV-type RNA ex-
ceed 55,000 copies per milliliter.
 
31
 
 As antiretroviral
therapy becomes available in less-developed coun-
tries, many HIV-infected persons who do not meet
these guidelines will be identified. Our data sug-
gest that multivitamins delay the onset of disease
progression and thus the time to the initiation of an-
tiretroviral therapy. Introducing these supplements
would preserve the use of antiretroviral drugs for
later stages of the disease, avert adverse events as-
sociated with them, and significantly reduce treat-
ment-related costs. The retail cost of a year’s sup-
ply of the multivitamins we used in this trial is
approximately $15 per person, and wholesale pric-
es are substantially lower. Given the impaired ab-
sorption and increased metabolic utilization of
nutrients among HIV-positive persons,
 
3
 
 we used
multiples of the recommended dietary allowances
in doses that were high enough to maximize the
likelihood of providing a beneficial effect but that
were within safe levels. The minimal dose of multi-
vitamins necessary for the best health outcomes
among HIV-infected persons is not known. We sug-
gest that supplementation with the doses used in
this trial be considered for HIV-infected persons
before the initiation of antiretroviral therapy.
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